Search

Your search keyword '"Pei, Lixia"' showing total 395 results

Search Constraints

Start Over You searched for: Author "Pei, Lixia" Remove constraint Author: "Pei, Lixia"
395 results on '"Pei, Lixia"'

Search Results

51. Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

52. Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

53. Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

54. Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

55. Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

57. Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

63. Microneedle-Mediated Biomimetic Cyclodextrin Metal Organic Frameworks for Active Targeting and Treatment of Hypertrophic Scars

64. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

68. A Bibliometric Analysis of Research Trends of Acupuncture Therapy in the Treatment of Migraine from 2000 to 2020

71. Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

72. sj-docx-1-aim-10.1177_09645284211027892 – Supplemental material for Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome

75. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

78. P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

85. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

89. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

91. Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome.

92. Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial

97. Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

99. Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

100. Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

Catalog

Books, media, physical & digital resources